SHR1210

DRUG6 trials

Sponsors

Peking University, Yanqiao Zhang, Qilu Hospital of Shandong University, Peking University Cancer Hospital & Institute, Fudan University

Conditions

Breast CancerGastric CancerHepatocellular CarcinomaMelanomaMetastatic CancerNK/T-cell Lymphoma

Phase 2

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Peking UniversityNK/T-cell Lymphoma

Start: 2018-10-20End: 2021-06-30Target: 61Updated: 2018-10-09

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Yanqiao ZhangHepatocellular Carcinoma

Start: 2019-01-30End: 2021-01-30Target: 30Updated: 2019-01-04

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

CompletedNCT03878472

Qilu Hospital of Shandong UniversityGastric Cancer

Start: 2019-04-01End: 2024-05-31Updated: 2024-12-16

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Peking University Cancer Hospital & InstituteMelanoma

Start: 2019-03-05End: 2021-04-10Target: 30Updated: 2019-05-20

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Fudan UniversityBreast Cancer, Metastatic Cancer

Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Peking University Cancer Hospital & InstituteMelanoma

Start: 2020-05-31End: 2023-02-28Target: 40Updated: 2020-05-21

Related Papers

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

2025-05-011 citations

Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.

Journal of Clinical Oncology2024-06-01

Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial

Cancer Research2024-05-02

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

JAMA Oncology2023-06-0124 citations

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.

2023-01-1219 citations

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.

2023-01-03163 citations

A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

Journal of Clinical Oncology2022-06-015 citations

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies

Frontiers in Pharmacology2021-11-092 citations

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

2021-10-2781 citations

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

Journal of Clinical Oncology2021-05-2012 citations

Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.

Journal of Clinical Oncology2021-05-204 citations